| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
As a protected amino acid derivative, H-D-Ser(tbu)-OBzl.HCl does not have a specific pharmacological target. Its primary role is as a chemical building block in peptide synthesis. Upon deprotection, D-serine may interact with D-serine receptors and transporters in biological systems. D-serine is a co-agonist at the NMDA receptor glycine site and plays important roles in neurotransmission and synaptic plasticity. The compound may also interact with enzymes involved in serine metabolism, including serine racemase and D-amino acid oxidase.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies have shown that amino acid derivatives like H-D-Ser(tbu)-OBzl.HCl influence cellular metabolism and protein synthesis. Research on serine derivatives has demonstrated their effects on cellular processes including neurotransmission, cell proliferation, and metabolic pathways. Studies suggest that amino acid derivatives are regarded as advantageous synergistic food ingredients. The D-enantiomer is of particular interest for studying the role of D-serine in NMDA receptor function and its implications in neurological disorders. |
| ln Vivo |
In vivo studies on D-serine derivatives have focused on their potential neurological effects. D-serine has been studied as a potential therapeutic agent for schizophrenia and other neurological disorders. Research in rodent models has shown that D-serine administration can modulate NMDA receptor function and affect cognitive performance. However, H-D-Ser(tbu)-OBzl.HCl specifically has limited published in vivo data as it is primarily used as a synthetic intermediate rather than a bioactive agent.
|
| Enzyme Assay |
In vitro enzyme assays for serine derivatives typically involve measuring their interaction with enzymes such as serine racemase or D-amino acid oxidase. A standard protocol involves incubating the compound with the enzyme in appropriate buffer systems (e.g., 50 mM Tris-HCl, pH 8.0) at 37°C. The reaction products are analyzed using HPLC or LC-MS. For NMDA receptor binding studies, radioligand binding assays with receptor preparations expressing NR1/NR2 subunits may be performed. IC₅₀ or EC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for H-D-Ser(tbu)-OBzl.HCl typically employ neuronal cell lines such as SH-SY5Y, PC12, or primary neuronal cultures to evaluate the compound's effects on NMDA receptor function and neuroprotection. A common protocol involves seeding cells in multi-well plates at appropriate densities and incubating overnight at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound (typically 1-1000 µM) for 24-72 hours. Cell viability is assessed using MTT or LDH assays. NMDA receptor function can be evaluated by measuring intracellular calcium levels using fluorescent probes or by electrophysiological recordings.
|
| Animal Protocol |
In vivo animal studies with serine derivatives typically utilize rodent models such as Sprague-Dawley rats or C57BL/6 mice. A standard protocol involves oral administration or intraperitoneal injection of the compound at doses ranging from 10-200 mg/kg body weight. Animals are maintained under standard laboratory conditions. Behavioral testing (e.g., Morris water maze, novel object recognition) may be performed to evaluate cognitive function. Brain tissue is harvested for measurement of D-serine levels, NMDA receptor function, and neurotransmitter levels.
|
| ADME/Pharmacokinetics |
H-D-Ser(tbu)-OBzl.HCl (molecular weight 231.68 g/mol) exhibits moderate lipophilicity. The compound has a melting point of 179-181°C. The tert-butyl protecting group is cleaved by strong acids (e.g., TFA), while the benzyl ester is removed by hydrogenolysis. The hydrochloride salt form enhances aqueous solubility and stability. Following absorption, the compound undergoes deprotection and normal serine metabolism. The D-enantiomer is metabolized by D-amino acid oxidase.
|
| Toxicity/Toxicokinetics |
The hydrochloride salt of H-D-Ser(tbu)-OBzl exhibits low toxicity, consistent with its nature as an amino acid derivative. Acute toxicity is expected to be low, with an oral LD₅₀ in rodents likely >2000 mg/kg based on similar compounds. The compound is not considered genotoxic or carcinogenic. Skin and eye contact may cause mild irritation. Inhalation of dust should be avoided. The compound is stable under normal storage conditions.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
H-D-Ser(tbu)-OBzl.HCl is supplied as a white to off-white solid powder with ≥98% purity. The compound has a molecular formula of C₁₀H₁₄ClNO₃. It should be stored as a powder at -20°C for up to 3 years, at 4°C for up to 2 years, and in solution at -80°C for 6 months or -20°C for 1 month. The product is for research use only and is not approved for human therapeutic applications.
|
| Molecular Formula |
C10H13NO3.HCL
|
|---|---|
| Molecular Weight |
231.67606
|
| Exact Mass |
231.066
|
| CAS # |
151651-44-4
|
| PubChem CID |
11776084
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
360.4ºC at 760 mmHg
|
| Melting Point |
179-181ºC
|
| Flash Point |
171.8ºC
|
| Vapour Pressure |
8E-06mmHg at 25°C
|
| LogP |
1.551
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
15
|
| Complexity |
178
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C(C=C1)COC(=O)[C@@H](CO)N.Cl
|
| InChi Key |
MGZWCDQAKCHOBX-SBSPUUFOSA-N
|
| InChi Code |
InChI=1S/C10H13NO3.ClH/c11-9(6-12)10(13)14-7-8-4-2-1-3-5-8;/h1-5,9,12H,6-7,11H2;1H/t9-;/m1./s1
|
| Chemical Name |
benzyl (2R)-2-amino-3-hydroxypropanoate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3163 mL | 21.5815 mL | 43.1630 mL | |
| 5 mM | 0.8633 mL | 4.3163 mL | 8.6326 mL | |
| 10 mM | 0.4316 mL | 2.1581 mL | 4.3163 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
